French 'reverse off-label' prescribing vote angers pharma industry
This article was originally published in SRA
Executive Summary
The pharmaceutical industry has hit out once more against the growing trend by governments in the EU to promote as a means of saving money the off-label use of drugs in indications for which an approved medicine is already available. The reaction came in response to a vote by the French National Assembly (the lower house) on 8 July to approve an amendment to the government's draft social security budget bill that would allow the off-label use of medicines as long as no identical product existed (previously it was only allowed if no authorized product existed)1.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.